Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 13/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16799802 | 1.00 | MAPK8 (0.50) | MAPK8MAPK9MAPK10RIPK2JUN | |
| SCHEMBL16802774 | 0.89 | MAPK8 (0.50) | MAPK8MAPK9MAPK10 | |
| SCHEMBL18148256 | 0.89 | MAPK8 (0.50) | MAPK8MAPK9MAPK10 | |
| SCHEMBL18148240 | 0.85 | MAPK8 (0.63) | MAPK8MAPK9MAPK10 | |
| SCHEMBL16802775 | 0.85 | MAPK8 (0.63) | MAPK8MAPK9MAPK10 | |
| SCHEMBL16802583 | 0.72 | MAPK8 (0.65) | MAPK8MAPK9MAPK10RIPK2JUN | |
| SCHEMBL18148247 | 0.72 | MAPK8 (0.65) | MAPK8MAPK9MAPK10RIPK2JUN | |
| SCHEMBL17910207 | 0.69 | MAPK8 (0.66) | MAPK8MAPK9MAPK10RIPK2JUN | |
| SCHEMBL16802771 | 0.69 | MAPK8 (0.66) | MAPK8MAPK9MAPK10RIPK2JUN | |
| SCHEMBL14391661 | 0.69 | MAPK8 (0.57) | MAPK8MAPK9MAPK10RIPK2JUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| EP-3076789-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | The Scripps Research Institute (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015084936-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015084936-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | MAPK3, MAP3K3, MAP3K2 | MAPK8 55/4885MAPK9 25/4885MAPK10 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.